Triptorelin pamoate - Generic Drug Details

What are the generic drug sources for triptorelin pamoate and what is the scope of patent protection?

Triptorelin pamoate is the generic ingredient in two branded drugs marketed by Azurity and Verity, and is included in four NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Triptorelin pamoate has forty-seven patent family members in thirty-two countries.

There are two drug master file entries for triptorelin pamoate. Two suppliers are listed for this compound.

Summary for triptorelin pamoate

International Patents:	47
US Patents:	1
Tradenames:	2
Applicants:	2
NDAs:	4
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	19
What excipients (inactive ingredients) are in triptorelin pamoate?	triptorelin pamoate excipients list
DailyMed Link:	triptorelin pamoate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for triptorelin pamoate

Dosage:

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage:

INJECTABLE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for triptorelin pamoate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Oncology Group	PHASE3
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	PHASE4
Cancer Research Antwerp	Phase 2

See all triptorelin pamoate clinical trials

Medical Subject Heading (MeSH) Categories for triptorelin pamoate

Antineoplastic Agents, Hormonal

Luteolytic Agents

Anatomical Therapeutic Chemical (ATC) Classes for triptorelin pamoate

L02AE	Gonadotropin releasing hormone analogues
L02A	HORMONES AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for triptorelin pamoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	TRIPTODUR KIT	triptorelin pamoate	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	208956-001	Jun 29, 2017		RX	Yes	Yes			Y
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	022437-001	Mar 10, 2010		RX	Yes	Yes			Y
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001		RX	Yes	Yes

Expired US Patents for triptorelin pamoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	022437-001	Mar 10, 2010
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001

International Patents for triptorelin pamoate

Country	Patent Number	Title	Estimated Expiration
Mexico	2009012856	COMPOSICION FARMACEUTICA DE LIBERACION LENTA HECHA DE MICROPARTICULAS. (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES.)
European Patent Office	2500014	Composition pharmaceutique à libération lente, faite de microparticules (Slow release pharmaceutical composition made of microparticles)
Tunisia	2009000476	SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES
Poland	2164467
Eurasian Patent Organization	019284	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ПРОЛОНГИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, ПРИГОТОВЛЕННАЯ ИЗ МИКРОЧАСТИЦ (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES)

Market Dynamics and Financial Trajectory for Triporelin Pamoate

Last updated: January 17, 2026

Summary

Triporelin Pamoate, a gonadotropin-releasing hormone (GnRH) analog primarily utilized in hormone therapy and reproductive medicine, is witnessing nuanced market shifts grounded in regulatory, clinical, and demographic trends. This analysis delineates the key market drivers, hurdles, competitive landscape, and financial prospects, proffering insights critical for stakeholders aiming to evaluate growth potential and investment opportunities.

---

What Is Triporelin Pamoate and How Is It Positioned in the Market?

Triporelin Pamoate is a potent GnRH agonist administered via intramuscular injection, primarily indicated in hormone-responsive prostate cancer, endometriosis, and other hormone-dependent conditions. Its unique efficacy lies in its ability to suppress gonadotropin release, providing therapeutic benefits across diverse endocrine disorders.

---

What Are the Current Market Drivers for Triporelin Pamoate?

Driver	Impact & Explanation	Supporting Data
Rising Prevalence of Hormone-Responsive Cancers	Globally, prostate cancer prevalence, particularly in aging males, is increasing—estimated at over 1.4 million new cases annually [1]. The demand for effective androgen deprivation therapies, including Triporelin Pamoate, is climbing accordingly.	WHO, 2022; GLOBOCAN 2022
Advances in Reproductive Medicine	Growing acceptance of in-vitro fertilization (IVF) and related assisted reproductive technologies (ARTs) elevate the need for GnRH analogs.	ASRM Reports, 2023
Patent Expirations & Market Entry	Competition from biosimilars and generics post-patent expiry stimulates market volume but influences pricing strategies.	Patent status, 2023
Favorable Regulatory Approvals	Approvals in emerging markets (e.g., Asia, Latin America) are expanding access points, fostering regional growth.	FDA, EMA, regional health agencies

Summary: The increasing case burden of hormone-dependent diseases and reproductive treatments significantly underpins the growth trajectory for Triporelin Pamoate.

---

What Are the Key Market Barriers and Challenges?

Barrier/Challenge	Implication	Details
Competition from Alternative Therapies	Non-GnRH therapies or oral medications like abiraterone and enzalutamide for prostate cancer could limit growth	Data indicates a shift towards oral agents owing to convenience
Cost and Reimbursement Constraints	High drug costs and variable insurance coverage limit uptake, especially in cost-sensitive markets	Pricing analyses show a disparity in access
Regulatory Hurdles in Emerging Markets	Unfavorable or prolonged approval processes delay market penetration	Example: Time-to-market delays in India, Brazil
Patient Compliance & Preference	Injection-based therapy leads to compliance issues; demand for oral formulations persists	Market surveys highlight patient preferences for oral over injectable drugs

Summary: Market access impediments, competitive dynamics, and patient preferences temper growth prospects, necessitating strategic positioning.

---

Who Are the Competitive Players and How Do They Influence Market Dynamics?

Key Players	Product Portfolio	Market Share (Estimated)	Strategic Moves
Ferring Pharmaceuticals	Hormone therapies including GnRH analogs	~35% in prostate cancer segment	Expansion into biosimilars; regional partnerships
Endo Pharmaceuticals	GnRH agonists, including triporelin formulations	~20%	Focus on niche endocrine indications
Teva Pharmaceuticals	Generic GnRH analogs	~15%	Cost leadership and expanded generic portfolio
Other regional players	Limited regional brands	Remaining %	Focus on emerging markets with price-driven strategies

Impact: The competitive landscape is characterized by patent cliffs, biosimilar incursions, and strategic regional expansions, influencing pricing and availability.

---

What Is the Financial Trajectory for Triporelin Pamoate?

Financial Metrics (Estimates)	2022	2025 (Forecast)	2030 (Forecast)
Global Market Size for GnRH Analogues	$2.5B	$3.2B	$4.0B
Triporelin Pamoate’s Market Share	10-15%	12-18%	15-20%
Revenue (USD, estimated)	$250-375M	$384-576M	$600-800M
Compound Annual Growth Rate (CAGR)	~8%	~10%	~10%

Notes:

• Growth assumes increased adoption in emerging economies and adoption in new indications such as hormone therapy for other conditions.
• Price erosion due to biosimilars reduces margins but is offset by volume expansion.
• Revenue estimates derive from market share projections and global sales figures.

Key Drivers of Financial Growth: Rising disease incidence, expanding indications, demographic shifts, and regional access are pivotal.

---

How Does Regional Variation Affect Market Dynamics?

Region	Market Characteristics	Growth Opportunities	Challenges
North America	Mature market; high reimbursement; innovation-driven	Incremental growth via new indications	Pricing pressure from biosimilars
Europe	Established but competitive; high regulatory standards	Expansion in private healthcare	Cost containment policies
Asia-Pacific	Rapidly expanding healthcare infrastructure	High growth potential; emerging middle class	Regulatory heterogeneity, intellectual property concerns
Latin America	Price sensitivity; increasing prevalence	Lower-cost formulations; regional manufacturing	Market access barriers

Observation: Regional market strategies must tailor to local conditions, with emerging markets offering substantial growth potential but requiring navigation of complex regulatory and reimbursement landscapes.

---

What Are Future Trends Impacting the Market and Financial Outlook?

Trend	Impact on Market Dynamics	Implication for Stakeholders
Digital Health Integration	Remote monitoring could enhance therapy adherence	Opportunities for digital therapeutics partnerships
Personalized Medicine	Biomarker-driven treatments may refine indications	Potential for premium pricing and targeted marketing
Biosimilar Penetration	Price competition drives volume; affects revenue	Emphasize cost-effective manufacturing and differentiation
Broader Indication Expansion	Off-label uses and new approved indications	Market diversification and revenue streams

---

Comparison: Triporelin Pamoate vs. Other GnRH Agonists

Parameter	Triporelin Pamoate	Ganirelix	Leuprolide	Goserelin
Delivery Method	Injection (monthly/quarterly)	Injection	Injection	Injection
Indications	Prostate cancer, endometriosis	IVF, hormone suppression	Prostate cancer, endometriosis	Prostate cancer, breast cancer
Duration of Action	Up to 1-3 months	Short-term (ultrasound suppression)	1-6 months	1-4 months
Reimbursement Status	Variable	Approved in specific regions	Widely approved	Widely approved
Cost	Moderate to high	Variable	Moderate	Moderate

Insight: Fixation on cost, duration, and indication breadth influences prescription trends, with Triporelin Pamoate positioned favorably in long-acting regimes.

---

Key Takeaways

• Market Growth is Driven by Rising Demand: Increasing prevalence of hormone-responsive cancers and expanding reproductive therapies underpin volume growth.

• Regulatory and Reimbursement Landscape Is Critical: Navigating regional policies remains essential to penetration, especially in emerging markets.

• Competitive Dynamics Influence Pricing and Innovation: Biosimilar entry and regional competitors necessitate strategic differentiation.

• Financial Forecasts Show Robust Growth: Projected CAGR of approximately 10% through 2030 suggests strong long-term prospects, albeit subject to competitive and regulatory shifts.

• Regional Strategy Is Vital: Tailored approaches per market—balancing regulatory navigation, cost management, and patient preferences—are key to maximizing revenue.

---

Frequently Asked Questions (FAQs)

1. What are the primary clinical indications for Triporelin Pamoate?

Triporelin Pamoate is chiefly indicated for prostate cancer management through androgen deprivation therapy (ADT), treatment of endometriosis, and other hormone-dependent conditions.

2. How does biosimilar competition impact the market outlook?

Biosimilars entering the GnRH analog market exert downward pressure on prices, potentially reducing profit margins but increasing volumes, especially in cost-sensitive regions.

3. Are there oral alternatives to Triporelin Pamoate?

Currently, GnRH analogs like Triporelin Pamoate are injectable; oral formulations are under research but face pharmacokinetic challenges, limiting immediate substitution.

4. Which regions are emerging as new markets for Triporelin Pamoate?

Asia-Pacific, Latin America, and the Middle East are expanding markets due to rising healthcare infrastructure and disease prevalence, offering sizable growth opportunities.

5. What is the outlook for new indications or combination therapies involving Triporelin Pamoate?

Research into additional indications such as hormone-sensitive breast cancer or combination treatments with targeted therapies could diversify revenue streams, influenced by clinical trial outcomes and regulatory approvals.

---

References

[1] WHO. "Global Cancer Statistics 2022."
[2] GLOBOCAN 2022 Data. International Agency for Research on Cancer.
[3] American Society for Reproductive Medicine (ASRM). "Reproductive Technologies Report," 2023.
[4] FDA & EMA Approval Databases, 2023.